Puma Biotech to pay PPD founder $22M in defamation suit from proxy fight | Fierce Pharma
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters
Puma's (PBYI) Earnings and Revenues Beat Estimates in Q1
Puma Biotechnology Surging
Puma Biotech Rebranding — Alex Maurer Designs
Puma Biotech Rebranding — Alex Maurer Designs
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology (Nasdaq:PBYI) - Stock Price, News & Analysis - Simply Wall St
Puma Biotech Defies Odds, Wins FDA Backing for Breast Cancer Drug | BioSpace
Puma Biotech plunges on drug side effects
Puma Biotech Gets $100M Loan to Boost Breast Cancer Drug - Los Angeles Business Journal
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotech (PBYI) Shows Fast-paced Momentum But Is Still a Bargain Stock
PBYI Stock Price and Chart — NASDAQ:PBYI — TradingView
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib | Nasdaq
Puma Biotech Rebranding — Alex Maurer Designs
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech's Overnight Billionaire On One Of His Keys To Success
Biotech Entrepreneur's Fortune Nearly Doubles After Strong Clinical Trials For Cancer Treatment
Puma shares nearly triple on drug news, but options smell 'fishy'
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
